Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vyvanse in preschool children with ADHD
NCT02466386Phase 3Completed
- Sponsor
- Takeda
- Start
- Aug 2015
- Primary completion
- Jan 2020
- Countries
- 1
01
Overview
A Phase 3 trial of lisdexamfetamine in attention deficit hyperactivity disorder (ADHD), sponsored by Takeda. Started Aug 2015; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02466386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02466386.